India pharmacovigilance status and scope to other Asian countries | 6255
Journal of Developing Drugs

Journal of Developing Drugs
Open Access

ISSN: 2329-6631

India pharmacovigilance status & scope to other Asian countries

Joint International Conference and Expo on Industrial Pharmacy & 5th Global Pharmacovigilance Summit

April 28-29, 2016 Dubai, UAE

Ismeet Kaur, V Kalaiselvan and G N Singh

Ministry of Health & Family Welfare, India

Posters & Accepted Abstracts: J Develop Drugs

Abstract :

WHO initiated International Drug Monitoring Programme after thalidomide tragedy. To expand the drug safety surveillance programme internationally, 32 Asian countries has enrolled under WHO Programme of International Drug Monitoring (WHO-PIDM). Asia PV has become an important public health issue as Asian Continent carry maximum number of world population. Indian Pharmacopoeia Commission is functioning as National Coordination Centre for Pharmacovigilance Programme of India (PvPI) from 2011. Within a short span of time, by 2015, India has not only set up the system of pharmacovigilance but also has set the standards for its effective functioning. Comparing other countries in the Asian Continent, India is the first country which has launched the nationwide helpline (toll free), consumer reporting form in different vernacular languages & Android Mobile App to report ADR by the general public. India has also reported more than 100 thousand ADRs reaching the quality score 0.93 WHO scale as regulator. Comparing to other Asian countries, India has excelled by developing different ADR reporting tools to create awareness to enhance PV system. These methods can add scope to other countries so as to promote patient safety.

Biography :